Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Eylea in macular edema secondary to CRVO
CTR20191812Phase 3Terminated
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of brolucizumab in macular edema, sponsored by Novartis. Started Sep 2019; status: terminated.
02
Drugs
brolucizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on CTR20191812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191812.